百克生物(688276.SH):上半年淨利潤1.38億元 同比增長23.54%
格隆匯8月15日丨百克生物(688276.SH)公佈半年度報吿,報吿期內公司實現營業總收入61,840.12萬元,上年同期55,964.43萬元,增加5,875.70萬元,增長10.50%;歸屬於母公司所有者的淨利潤13,760.45萬元,上年同期11,138.34萬元,增加2,622.11萬元,增長23.54%。
報吿期內,公司始終秉承創新為企業基礎生命力的理念,着力優化研發項目管理機制,建立了有效的預警機制、階段性報吿機制等,統籌佈局長期、中期、短期研發項目。聚焦創新性疫苗、單克隆抗體等公司優勢產品,實現生產一代、研發一代、儲備一代,研發投入8,552.99萬元,佔營業收入13.83%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.